Asia
Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
Astellas Pharma Inc. today announced that roxadustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase activity, met its primary endpoints in the Phase 3 ALPS study
Clinical data generated for submission process to be presented at international scientific congress in 2018
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
Management will host a conference call and webcast today, Monday, 17 September at 8:30am ET/8:30pm SGT.
New report highlights major gaps in understanding and significant misperceptions about blood cancer in the region, with one in two Japanese and one in four Chinese unable to name a single symptom of the disease
Han expounds on his Theory of Negative Trigger as it relates to seasonal/yearlong allergies.
BeiGene to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies
CBT Pharmaceuticalstoday announced the initiation of the APOLLO Oncology Clinical Trials Program.
A second former GlaxoSmithKline scientist has pled guilty to stealing trade secrets as part of a scheme to benefit a startup China-based pharmaceutical company he helped establish.
PRESS RELEASES